Pleuropulmonary infections caused by Mycobacterium bovis: a re-emerging disease  by Esteban, J. et al.
RESEARCH NOTE
Pleuropulmonary infections caused by
Mycobacterium bovis: a re-emerging disease
J. Esteban1, P. Robles1, M. Soledad Jime´nez2
and M. L. Ferna´ndez Guerrero1
1Division of Infectious Diseases and Department
of Medical Microbiology, Fundacio´n Jime´nez
Dı´az, Universidad Auto´noma de Madrid,
Madrid and 2Mycobacteria Reference Laborat-
ory, Centro Nacional de Microbiologı´a, Maja-
dahonda, Spain
ABSTRACT
Between 1980 and 2003, 13 patients (0.95% of all
cases of tuberculosis) at a 600-bed university
hospital in Madrid, Spain, were diagnosed with
Mycobacterium bovis infection. All 13 cases oc-
curred between 1994 and 1999; the mean age of
the patients was 50 years (range 23–83 years), and
77% were males. Four (30%) patients were also
positive for human immunodeﬁciency virus
(HIV). The most frequent localisation of the
disease was the lung (ten patients; 77%). Seven
patients, including four HIV-positive patients
who died, had multidrug-resistant M. bovis infec-
tion. No other patient died, including two
HIV-negative patients with multidrug-resistant
disease.
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Mycobacterium bovis is a member of the Mycobac-
terium tuberculosis complex and is genetically
indistinguishable from M. tuberculosis [1].
Although phenotypic differentiation between
these organisms is difﬁcult, this process remains
important because of epidemiological and thera-
peutic considerations [2,3]. Once considered a
common cause of tuberculosis, M. bovis is now
isolated rarely in developed countries [4], but
there have been recent reports of infections
caused by multidrug-resistant M. bovis (MDRMB)
[5,6], including both sporadic cases and epidemic
outbreaks [7–10]. The present study describes
experience with M. bovis infections in Madrid,
including cases of MDRMB infections.
The study reviewed all patients from whom
M. bovis was isolated between January 1980 and
December 2003, excluding patients with bacille
Calmette–Gue´rrin strains, according to a prede-
ﬁned protocol that investigated demographics,
symptoms and signs of infection, blood tests,
radiological studies, treatment and outcome.
During the study period, samples were proc-
essed according to methods published previ-
ously [11]. Brieﬂy, after decontamination with
N-acetyl-cysteine-NaOH, respiratory samples
were inoculated on to Middlebrook 7H11 agar
plates (Becton Dickinson, Franklin Lakes, NJ,
USA) and Lowenstein–Jensen and Coletsos
slants (Pronadisa, Torrejo´n de Ardoz, Madrid,
Spain), while non-respiratory samples were
inoculated on to Middlebrook 7H11 agar plates
and Lowenstein–Jensen slants, as well as into
different liquid media (MB-Check, BACTEC
9000 series and MGIT 960; Becton Dickinson),
depending on the year of processing. All media
were incubated at 37C for up to 8 weeks. All
mycobacterial isolates were identiﬁed with bio-
chemical tests and DNA probes (Accuprobe;
bioMe´rieux, Marcy l’Etoile, France), with conﬁr-
mation of identity and susceptibility testing
being performed at the Centro Nacional de
Microbiologı´a (Majadahonda, Spain). MDRMB
isolates were sent to the Mycobacteria Laborat-
ory at Zaragoza University (Dr C. Martı´n) as
part of a multicentre study of the molecular
epidemiology of multidrug-resistant M. tubercu-
losis complex strains in Spain [12].
During the study period, 1366 patients were
diagnosed with tuberculosis following culture,
andM. boviswas isolated from 13 of these patients
(0.95% of all cases of tuberculosis). The details of
these 13 patients are shown in Table 1. All the
M. bovis isolates were identiﬁed between 1994 and
1999, with peaks of incidence associated with the
presence of cases of MDRMB disease. All
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MDRMB strains had the same restriction frag-
ment length polymorphism pattern as other
MDRMB strains involved in hospital outbreaks
of infection in Spain [13]. No M. bovis isolates
were detected after 1999.
The mean age of the patients was 50 years
(range 83–23 years) and 77% were males. Four
(30%) patients were positive for human immu-
nodeﬁciency virus (HIV) and had AIDS. Other
underlying diseases included silicosis, lung ﬁbro-
sis secondary to radiotherapy, diabetes mellitus,
corticosteroid therapy and malnutrition. Four
patients had no chronic debilitating disease pre-
disposing to tuberculosis. The mean time between
the onset of symptoms and the ﬁrst medical
consultation was 51.2 days (range 4–120 days),
and the mean time for detection of acid-fast bacilli
was 9.5 days (range 1–30 days). The site involved
most frequently was the lung (ten patients; 77%).
The main symptoms were cough, fever, malaise,
weight loss, pleuritic chest pain and haemoptysis
(Table 2). The most frequent abnormalities were
an increased erythrocyte sedimentation rate and
anaemia (nine cases), and hyponatraemia
(Na < 134 mEq ⁄L; seven cases); one patient had
hypercalcaemia. All HIV-infected patients had
CD4 cell counts < 200 cells ⁄mL (mean
72 cells ⁄mL; typical deviation 71 cells ⁄mL).
X-ray ﬁlms of the chest showed abnormalities in
ten patients: upper right lobe inﬁltrates (70%),
cavitation (50%), upper left lobe inﬁltrates (20%)
and lower left lobe inﬁltrates (10%).
While all patients with MDRMB disease had
fever, patients without multiresistant strains did
not develop fever (p < 0.001). Other systemic
symptoms (p 0.029), increased sedimentation rate
and hyponatraemia also appeared more fre-
quently among MDRMB cases (p 0.049). The
association between MDRMB and HIV infection
was frequent, but not signiﬁcant (p 0.069), per-
haps because of the small number of cases. HIV-
infected patients with MDRMB disease had a
poorer prognosis and a higher probability of
mortality compared with HIV-negative patients
(p 0.14). One case of MDRMB disease detected in
a healthcare worker was cured with a combina-
tion of rifampicin, isoniazid and pyrazinamide.
Infections caused by M. bovis following inges-
tion of unpasteurised dairy products were com-
mon in the past. Nowadays, such infections are
rare in developed countries [4], butM. bovis is still
isolated occasionally from patients with tubercu-
losis, and correct identiﬁcation is important for
epidemiological reasons. In addition, because
M. bovis is resistant to pyrazinamide, its isolation
has therapeutic implications [4,14,15]. Moreover,
the emergence of MDRMB is an important devel-
opment in M. bovis disease, with outbreaks and
sporadic infections caused by MDRMB already
having been reported in Spain [7,8,10]. The
fact that most of these cases have been linked
epidemiologically indicates the potential for
Table 1. Details of patients with Mycobacterium bovis infection
Case Yeara Age (years) Underlying disease Localisation Positive sample MDRMB Therapy Outcome
1 1994 27 AIDS Lung Sputum, BAL Yes I, R, E, S, O Unknown
2 1994 38 AIDS Lung Sputum, BAL Yes I, R, E, S Death
3 1995 23 AIDS Disseminated Liver biopsy Yes I, R, P, S Death
4 1995 77 Malnutrition Lung Sputum Yes I, R, P Death
5 1995 40 AIDS Lung Sputum, BAL Yes I, R, S Death
6 1996 83 None Lung BAL No None Death
7 1997 79 None Vertebral Bone biopsy No I, R, P Cure
8 1997 55 Lung ﬁbrosis Lung Sputum, BAL No I, R, P Cure
9 1998 32 None Lung Sputum Yes I, R, P Cure
10 1998 41 Diabetes, corticoid therapy Lung Sputum Yes I, R, P, second-line drugs, including
amoxycillin–clavulanic acid
Cure
11 1999 23 None Lung Sputum No I, R, P Cure
12 1999 67 Silicosis Lung BAL No I, R, P Cure
13 1999 69 None Skin Skin biopsy No I, R, P Cure
aYear of isolation.
BAL, bronchoalveolar lavage; MDRMB, multidrug-resistant Mycobacterium bovis; I, isoniazid; R, rifampicin; P, pyrazinamide; E, ethambutol; S, streptomycin; O, oﬂoxacin.
Table 2. Clinical symptoms of 13 patients with Mycobac-
terium bovis infection
Symptom Frequency (%) No. of cases
Cough 61.5 8
Fever 53.8 7
Malaise 53.8 7
Weight loss 30 4
Chest pain 7.7 1
Haemoptysis 7.7 1
Back pain 7.7 1
Other 15.4 2
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transmission of M. bovis in the hospital environ-
ment. The mobility of HIV-infected patients
between hospitals in Spain and abroad is prob-
ably responsible for the spread of infection
throughout the entire country and, as documen-
ted in one case, to The Netherlands [5]. In the
present series, all HIV-infected patients with
MDRMB infection had a severe disease, which
indicates a high susceptibility in these patients to
this particular organism, with the risk of devel-
oping a severe disease unresponsive to conven-
tional anti-tuberculosis therapy. Fortunately, two
of the HIV-negative patients with MDRMB dis-
ease were cured, which suggests that the integrity
of the immune system plays a paramount role in
the outcome [16,17].
Infections caused by susceptible strains were
also represented in the present series. Seven of the
patients had pulmonary tuberculosis, and two
had extra-pulmonary disease, i.e., vertebral osteo-
myelitis and skin infection, respectively. Histor-
ically, intestinal infection was the most frequent
manifestation of M. bovis disease, but such infec-
tions have not been seen in recent years, during
which most cases have been associated with
pulmonary disease and respiratory transmission
[4,18]. One of the patients had contact with
animals as a veterinary student, but there was
no special risk-factor for M. bovis disease for the
others. None of the patients was an immigrant
from a developing country, although an increas-
ing number of immigrants have been observed
among cases of tuberculosis in our hospital [19].
However, it is possible that a re-emergence of
M. bovis disease, perhaps in the form of intestinal
or lymphatic tuberculosis, is occurring in indi-
viduals coming to the European Union from
countries with deﬁcient sanitary systems. The
appearance of MDRMB disease in HIV-infected
patients shows a new face of this infection. The
fact that M. bovis infection could be maintained in
the population through respiratory transmission
should be taken into account when formulating
policies and control measures for the disease in
Europe.
REFERENCES
1. Wayne LG, Kubica GP. Genus Mycobacterium. In: Sneath
PHA, Mair NS, Sharpe ME, Holt JG, eds. Bergey’s manual of
systematic bacteriology. Baltimore: Williams & Wilkins,
1986; 1436–1457.
2. Bouvet E, Casalino E, Mendoza Sassi G et al. A nosocomial
outbreak of multidrug-resistant Mycobacterium bovis
among HIV-infected patients. A case-control study. Aids
1993; 7: 1453–1460.
3. Gutierrez MC, Bouvet E, Blazquez J, Vincent V. Identiﬁ-
cation as Mycobacterium tuberculosis of previously
described M. bovis multidrug-resistant strains. Lancet 1998;
351: 758.
4. Dankner WM, Waecker NJ, Essey MA, Moser K,
Thompson M, Davis CE. Mycobacterium bovis infections in
San Diego: a clinicoepidemiologic study of 73 patients and
a historical review of a forgotten pathogen. Medicine
(Baltimore) 1993; 72: 11–37.
5. Schultsz C, Kuijper EJ, van Soolingen D, Prins JM. Dis-
seminated infection due to multidrug-resistant Mycobac-
terium bovis in a patient who was seropositive for human
immunodeﬁciency virus. Clin Infect Dis 1996; 23: 841–843.
6. Palenque E, Villena V, Rebollo MJ, Jimenez MS, Samper S.
Transmission of multidrug-resistantMycobacterium bovis to
an immunocompetent patient. Clin Infect Dis 1998; 26: 995–
996.
7. Guerrero A, Cobo J, Fortun J et al.Nosocomial transmission
of Mycobacterium bovis resistant to 11 drugs in people with
advanced HIV-1 infection. Lancet 1997; 350: 1738–1742.
8. Blazquez J, Espinosa de los Monteros LE, Samper S et al.
Genetic characterization of multidrug-resistant Mycobac-
terium bovis strains from a hospital outbreak involving
human immunodeﬁciency virus-positive patients. J Clin
Microbiol 1997; 35: 1390–1393.
9. Gori A, Marchetti G, Catozzi L et al. Molecular epidemi-
ology characterization of a multidrug-resistant Mycobacte-
rium bovis outbreak amongst HIV-positive patients. AIDS
1998; 12: 445–446.
10. Rivero A, Marquez M, Santos J et al. High rate of tuber-
culosis reinfection during a nosocomial outbreak of
multidrug-resistant tuberculosis caused by Mycobacterium
bovis strain B. Clin Infect Dis 2001; 32: 159–161.
11. Metchock BG, Nolte FS, Wallace RJ. Mycobacterium. In:
Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH,
eds. Manual of clinical microbiology, 7th edn. Washington,
DC: ASM Press, 1999; 399–437.
12. Samper S, Iglesias MJ, Tello O. The Spanish multidrug
resistant tuberculosis network. Eurosurveillance 2000; 5: 43–
45.
13. Samper S, Martin C, Pinedo A et al. Transmission between
HIV-infected patients of multidrug-resistant tuberculosis
caused by Mycobacterium bovis. AIDS 1997; 11: 1237–1242.
14. Haas DW, Des Prez RM. Mycobacterium tuberculosis. In:
Mandell GL, Bennett JE, Dolin R, eds. Principles and practice
of infectious diseases, 4th edn. New York: Churchill Liv-
ingstone, 1995; 2213–2243.
15. American Thoracic Society, Centers for Diseases Control,
Infectious Diseases Society of America. Treatment of
tuberculosis. MMWR 2003; 52: 1–80.
16. Snider DE, Raviglione M, Kochi A. Global burden of tuber-
culosis. In: Bloom BR, ed. Tuberculosis: pathogenesis, protec-
tion and control. Washington, DC: ASM Press, 1994; 3–11.
17. Robles P, Esteban J, Ferna´ndez-Guerrero ML. Pulmonary
tuberculosis due to multidrug-resistant Mycobacterium
bovis in a healthy host. Clin Infect Dis 2002; 35: 212.
18. Smith RM, Drobniewski F, Gibson A et al. Mycobacterium
bovis infection, United Kingdom. Emerg Infect Dis 2004; 10:
539–541.
842 Clinical Microbiology and Infection, Volume 11 Number 10, October 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 834–855
19. Esteban J, Granizo JJ, A´lvarez-Castillo MC, Soriano F.
Drug resistance among Mycobacterium tuberculosis strains
in immigrants: is there a real threat everywhere? Clin
Microbiol Infect 2004; 10: 335–336.
RESEARCH NOTE
Use of rifampicin and ciproﬂoxacin
combination therapy after surgical
debridement in the treatment of early
manifestation prosthetic joint infections
J.-E. Berdal1, I. Skra˚mm2, P. Mowinckel3,
P. Gulbrandsen3 and J. V. Bjørnholt1
1Medical Department, 2Orthopaedic
Department, Akershus University Hospital,
Nordbyhagen and 3Health Service Research
Center, Oslo, Norway
ABSTRACT
Prosthetic joint infections are difﬁcult to eradicate,
and antibiotic and surgical treatment strategies
lack standardisation. The present study followed
29 patients (median age 72 years, median Ameri-
can Society of Anesthesia score of two) with early
prosthetic joint infections. Treatment consisted
of device retention, surgical debridement and
therapy with rifampicin and ciproﬂoxacin for
3 months. This treatment regimen failed in ﬁve
patients during the study, with a median obser-
vation period of 674 days. The results of this
study conﬁrm the ﬁndings of the only previous
study on device retention with antibiotic
treatment.
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Infections of orthopaedic prostheses can be a
devastating experience for patients and surgeons
alike, and greatly increase the morbidity and costs
associated with joint replacement surgery [1]. The
incidence of such infections has declined steadily
[2] and should not exceed 1–2%. However,
absolute numbers have been less affected, as the
number of procedures performed has increased
greatly [3]. There is no general consensus on the
management of such patients, and there is an
absence of adequate clinical studies. Although
small in terms of the number of patients enrolled,
the study of Zimmerli et al. [4] showed that
revision surgery without removal of the pros-
thesis, combined with treatment for 3 months
(hip replacements) or 6 months (knee replace-
ments) with rifampicin and ciproﬂoxacin, yielded
increased cure rates, compared with revision
surgery and ciproﬂoxacin monotherapy, for early
manifestation (< 3 months after surgery) implant
infections. The time of manifestation of infection
is of particular importance. The prospects for a
cure without removal of the prosthesis are
reduced greatly for infections with delayed
(> 3 months to < 2 years after surgery) or late
(> 2 years after surgery) manifestations [5,6]. The
aim of the present study was to examine whether
the results obtained by Zimmerli et al. [4] could be
reproduced outside the setting of a randomised
controlled study.
Twenty-nine consecutive patients with pros-
thetic joint infection, diagnosed within 3 months
of implant surgery, were enrolled in the study
between September 2000 and June 2003. Infections
following total hip and knee replacements, inser-
tions of hemi-prostheses, and revision arthropla-
sties were included. Fixation device infections
were excluded. The American Society of Anesthe-
sia score was used as a measure of co-morbidity.
Patients (Table 1) were assessed upon enrolment,
and after 3, 12 and, if possible, ‡ 24 months. The
CDC deﬁnition for deep incisional surgical site
infection with an implant was used [7]. Treat-
ment failure was deﬁned as the presence of local
signs of infection, radiological signs of infection,
peripheral white cell counts of > 11 · 109 ⁄mL
and C-reactive protein levels of > 7 mg ⁄mL.
Microbial isolates were identiﬁed using standard
techniques [8]. Primary rifampicin resistance in
staphylococci is exceedingly rare in Norway, and
rifampicin susceptibility testing was thus not
performed.
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